Pfizer announces FDA acceptance of and priority review designation for biologics license application for investigational meningococcal B vaccine
15 August 2014 | By Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for bivalent recombinant LP2086...